Insider · CIK 0001991929
Kendra Adams
cfoofficer
Files at CCCC (C4 Therapeutics, Inc.). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 18, 2026 | CCCC C4 Therapeutics, Inc. | MOption exercise Common Stock | +6,250 | $0.00 | $0 | 385,098 | 21 d ago |
| Sep 18, 2026 | CCCC C4 Therapeutics, Inc. | FTax withholding Common Stock | -2,775 | $3.39 | $9,407 | 382,323 | 21 d ago |
| Sep 18, 2025 | CCCC C4 Therapeutics, Inc. | MOption exercise Common Stock | +6,250 | $0.00 | $0 | 165,117 | Sep 19, 2025 |
| Sep 18, 2025 | CCCC C4 Therapeutics, Inc. | FTax withholding Common Stock | -2,775 | $3.32 | $9,213 | 162,342 | Sep 19, 2025 |
| Feb 13, 2025 | CCCC C4 Therapeutics, Inc. | FTax withholding Common Stock | -1,863 | $3.20 | $5,962 | 82,576 | Feb 18, 2025 |
| Feb 14, 2025 | CCCC C4 Therapeutics, Inc. | AGrant or award Common Stock | +87,100 | $0.00 | $0 | 169,676 | Feb 18, 2025 |
| Feb 14, 2025 | CCCC C4 Therapeutics, Inc. | FTax withholding Common Stock | -4,559 | $3.18 | $14k | 165,117 | Feb 18, 2025 |
| Feb 14, 2025 | CCCC C4 Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +130,600 | $0.00 | $0 | 130,600 | Feb 18, 2025 |
| Nov 7, 2024 | CCCC C4 Therapeutics, Inc. | MOption exercise Common Stock | +3,750 | - | - | 85,541 | Nov 12, 2024 |
| Nov 7, 2024 | CCCC C4 Therapeutics, Inc. | FTax withholding Common Stock | -1,102 | $6.04 | $6,656 | 84,439 | Nov 12, 2024 |
| Nov 7, 2024 | CCCC C4 Therapeutics, Inc. | MOption exercise Performance Restricted Stock Unitsderivative | -3,750 | $0.00 | $0 | 10,500 | Nov 12, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.